Patients will be administered oral capsules once daily for ten consecutive days. Credit: New Africa via Shutterstock.com.

The IMCA centre’s ethics committee in Israel has approved Clearmind Medicine’s CM-CMND-001 Phase I/II clinical trial of MEAI-based CMND-100 compound to treat alcohol use disorder (AUD).

The single and multiple-dose, multinational, multi-centre study is designed to evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in healthy volunteers and AUD subjects.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Finding the tolerable dose and describing the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated CMND-100 doses in healthy subjects and those with AUD is the primary endpoint of the study.

Evaluation of CMND-100’s efficacy in the reduction of drinking patterns and craving, in moderate-to-severe AUD subjects is the secondary endpoint.

Patients will be administered oral capsules once daily for ten consecutive days. During the trial period, they will report their drinking patterns and craving for alcohol and cigarettes.

Sheba Medical Center in the Tel Aviv suburb of Ramat Gan Psychiatric Division head professor Mark Weiser will lead the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Clearmind CEO Dr Adi Zuloff-Shani said, “CMND-100 was shown to cause a significant and immediate reduction of alcohol cravings and consumption in pre-clinical studies with a high safety profile.

“As a result, we believe that CMND-001 holds tremendous potential as an alternative to current approaches. Moreover, CMND-100 is intended as a once-a-day oral capsule that can be taken from the privacy of one’s home.

“With CMND-100, we aim to revolutionise AUD treatment and improve patients’ compliance to therapy compared to other marketed pharmacotherapies.”

The company plans to expand the study to two additional sites in the US, upon signing an agreement with local sites.